A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
-
- Xiangyang Chi
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Renhong Yan
- Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang Province, China.
-
- Jun Zhang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Guanying Zhang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Yuanyuan Zhang
- Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang Province, China.
-
- Meng Hao
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Zhe Zhang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Pengfei Fan
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Yunzhu Dong
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Yilong Yang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Zhengshan Chen
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Yingying Guo
- Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang Province, China.
-
- Jinlong Zhang
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Yaning Li
- Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.
-
- Xiaohong Song
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Yi Chen
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Lu Xia
- Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang Province, China.
-
- Ling Fu
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Lihua Hou
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Junjie Xu
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Changming Yu
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Jianmin Li
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
-
- Qiang Zhou
- Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang Province, China.
-
- Wei Chen
- Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing 100071, China.
抄録
<jats:title>Hitting SARS-CoV-2 in a new spot</jats:title> <jats:p> A key target for therapeutic antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the spike protein, a trimeric protein complex with each monomer comprising an S1 and an S2 domain that mediate binding to host cells and membrane fusion, respectively. In addition to the receptor binding domain (RBD), S1 has an N-terminal domain (NTD). In searching for neutralizing antibodies, there has been a focus on the RBD. Chi <jats:italic>et al.</jats:italic> isolated antibodies from 10 convalescent patients and identified an antibody that potently neutralizes the virus but does not bind the RBD. Cryo–electron microscopy revealed the epitope as the NTD. This NTD-targeting antibody may be useful to combine with RBD-targeting antibodies in therapeutic cocktails. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6504" page="650" related-article-type="in-this-issue" vol="369" xlink:href="10.1126/science.abc6952">650</jats:related-article> </jats:p>
収録刊行物
-
- Science
-
Science 369 (6504), 650-655, 2020-08-07
American Association for the Advancement of Science (AAAS)